D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
PP&E Gross
ÂĄ104.8m
CAGR 3-Years
90%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
PP&E Gross
ÂĄ9.3B
CAGR 3-Years
54%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
PP&E Gross
ÂĄ2.9B
CAGR 3-Years
46%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
PP&E Gross
ÂĄ1.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
PP&E Gross
ÂĄ5.1B
CAGR 3-Years
20%
CAGR 5-Years
25%
CAGR 10-Years
24%
Imeik Technology Development Co Ltd
SZSE:300896
PP&E Gross
ÂĄ300.4m
CAGR 3-Years
26%
CAGR 5-Years
15%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's PP&E Gross?
PP&E Gross
104.8m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's PP&E Gross amounts to 104.8m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
65%

Over the last year, the PP&E Gross growth was -1%. The average annual PP&E Gross growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 90% over the past three years , 65% over the past five years .

Back to Top